AUSTIN, TX, August 5, 2025 — Shattuck Labs, Inc. (NASDAQ: STTK) has announced a securities purchase agreement for a private placement expected to generate approximately $103 million before expenses. The funding is earmarked for advancing SL-325 through Phase 2 clinical trials, including studies for Inflammatory Bowel Disease (IBD) and other autoimmune diseases.
The private placement was led by OrbiMed, with participation from new and existing investors such as Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital.
The agreement includes the issuance of 15,225,158 shares of common stock and pre-funded warrants for 37,410,188 shares, along with accompanying warrants for 52,635,346 shares. The funds are anticipated to support operations into 2029.
According to Taylor Schreiber, M.D., Ph.D., CEO of Shattuck, the financing will enable the company to transition into Phase 2 clinical trials for SL-325, a DR3 blocking antibody intended for development in Crohn’s disease, ulcerative colitis, and other autoimmune and inflammatory diseases. Enrollment in the Phase 1 clinical trial for SL-325 is expected to begin this quarter, pending regulatory alignment.
The initial gross proceeds are expected to be about $46 million, with a potential additional $57 million if the common stock warrants are fully exercised. The closing of the private placement is contingent upon IND clearance for SL-325 and other customary conditions.
Wedbush & Co., LLC served as the sole placement agent for the private placement.
Contact:
Conor Richardson
Vice President of Investor Relations
InvestorRelations@ShattuckLabs.com
Source: Shattuck Labs, Inc.
